Sanofi announced early results of phase 2 trial of IL6 inhibitor, sarilumab, showing benefit only in Critical COVID-19 pts. 457 pts given IV Kevzara 400 mg vs 200 mg vs PBO , high dose had fewer deaths (32 v 46 v 55%) & more D/C (53 v 39 v 41%). https://t.co/6q21qJNj2C
Links:
Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial i…
https://bit.ly/2y6rcIm
Apr-27-2020
